Basic Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2021; 12(7): 1102-1115
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.1102
Decarboxylated osteocalcin, a possible drug for type 2 diabetes, triggers glucose uptake in MG63 cells
Shi Jin, Xiao-Cen Chang, Jing Wen, Jing Yang, Na Ao, Ke-Ying Zhang, Lin-Na Suo, Jian Du
Shi Jin, Xiao-Cen Chang, Jing Wen, Jing Yang, Na Ao, Lin-Na Suo, Jian Du, Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China
Ke-Ying Zhang, Department of Endocrinology, The Fifth People’s Hospital of Shenyang, Shenyang 110023, Liaoning Province, China
Author contributions: Jin S designed the study, performed the experiments and data analysis, the obtained the funding, and contributed to paper writing; Chang XC and Ao N contributed to obtaining the funding and performed the experiments; Wen J and Yang J contributed to paper writing; Zhang KY and Suo LN performed the data analysis; Du J supervised the project, reviewed and edited the manuscript, and managed the submission process.
Supported by Provincial Science and Technology Department Natural Fund Guidance Project, No. 2019-ZD-0774; National Natural Science Foundation of China, No. 81470998; Liaoning Ministry of Education, No. LQNK201715; and Liaoning Provincial Doctor Start up Fund, No. 20180540008.
Institutional review board statement: Because the objects of this study were cells, not the human beings or animals, the study was not reviewed and approved by any institutional review board.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Du, PhD, Professor, Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang 110032, Liaoning Province, China. dujian_1962@163.com
Received: January 21, 2021
Peer-review started: January 21, 2021
First decision: March 16, 2021
Revised: April 5, 2021
Accepted: June 4, 2021
Article in press: June 4, 2021
Published online: July 15, 2021
Core Tip

Core Tip: Uncarboxylated osteocalcin (GluOC) has been reported to improve glucose metabolism and prevent type 2 diabetes. GluOC can increase the glucose uptake in a variety of cells. In this study, MG63 cells were treated with different concentrations of decarboxylated osteocalcin (dcOC) for 1 h and 72 h to observe the changes in glucose uptake, proliferation, and alkaline phosphatase (ALP) activity, as well as possible signaling pathway. Short- or long-term intervention with dcOC in vitro can increase glucose uptake and promote the proliferation and ALP activity of MG63 cells. This effect may occur through the PI3K/Akt, hypoxia-inducible factor 1 alpha, and glucose transporter 1 signaling factors.